For International Women’s Day 2022, and especially the global theme of #BreaktheBias, we have two treats for novel and disruptive healthcare and life sciences innovators.
Read MoreFind out what Healthcare and Life Sciences businesses and investors anticipate for the healthcare industry in 2022.
Read MoreFor the first time, the Drug Enforcement Agency (“DEA”) is becoming directly involved in the telepharmacy space, an industry that the DEA has not previously regulated aside from the loose application of its existing regulations governing online pharmacies. Find out what this means for your business and how you can submit comments to the DEA directly in this post.
Read MoreThe U.S. Department of Justice (DOJ) just sent a strong message to pharmaceutical and biotechnology companies who rely on contracted sales teams to push their products into the market: “commission-based compensation violates the Federal Anti-Kickback Statute (AKS)”.
This message seems to undermine years’ worth of relative stability in how these companies evaluate risks associated with commission-based compensation that does not fit squarely into a legal safe harbor under the AKS.
Read More